Newsroom

May 2016

• Press release May 25, 2016

  Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event

  Outlines actions underway to accelerate launch of Entresto®, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx® Highlights…
• Press release May 24, 2016

  Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency

  Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label…
• Press release May 21, 2016

  Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals

  US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto[1] Updated…
• 
  Story May 20, 2016 From Our Labs

  Building brain organoids to shed light on disease

  Three-dimensional clusters of human neurons could allow scientists to watch neurological diseases develop in the lab.

• 
  Story May 20, 2016 From Our Labs

  With a "brain in a dish," researchers take on neurological disorders

  Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.

• Press release May 19, 2016

  Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure

  Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program…
• Press release May 18, 2016

  Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting

  First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna® both in front-line and second-line following Glivec®*  First genomic analysis and 3-year…
• Press release May 18, 2016

  MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer

  Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-…
• Press release May 17, 2016

  Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis

  Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis  Paul Hudson and Bruno Strigini appointed to the…
• Press release May 17, 2016

  Novartis renforce la division Pharmaceuticals par la création de deux unités d'affaires, Novartis Pharmaceuticals et Novartis Oncology, et nomme de nouveaux dirigeants à son Comité de direction

  Paul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis   Paul Hudson et Bruno Strigini sont nommés au Comité…
• Press release May 17, 2016

  Novartis fokussiert ihre Division Pharmaceuticals durch Schaffung der Geschäftseinheiten Novartis Pharmaceuticals und Novartis Oncology und beruft deren Leiter in die Geschäftsleitung von Novartis

  Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen   Paul Hudson und Bruno Strigini werden in…
• Featured News May 17, 2016

  Fighting high blood pressure in Vietnam

  The Novartis Foundation is launching a blood pressure management program in Vietnam as part of its larger effort to combat the rise of chronic diseases in urban areas of developing countries.